Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 225Lymphoma, Large B-Cell, Diffuse 160Small Cell Lung Carcinoma 156Precursor Cell Lymphoblastic Leukemia-Lymphoma 143Lymphoma, Non-Hodgkin 139Leukemia 135Leukemia, Myeloid, Acute 117Hodgkin Disease 106Lung Neoplasms 99Burkitt Lymphoma 99Lymphoma, Follicular 85Lymphoma, Mantle-Cell 76Lymphoma, Large-Cell, Immunoblastic 68Carcinoma, Non-Small-Cell Lung 61Neuroblastoma 60Leukemia, Lymphocytic, Chronic, B-Cell 56Recurrence 53Multiple Myeloma 52Lymphoma, B-Cell, Marginal Zone 43Congenital Abnormalities 43Sarcoma 39Central Nervous System Neoplasms 39Myelodysplastic Syndromes 35Brain Neoplasms 34Ovarian Neoplasms 32Leukemia, Myelomonocytic, Acute 32Lymphoma, B-Cell 31Leukemia, Monocytic, Acute 31Leukemia, Erythroblastic, Acute 31Testicular Neoplasms 30

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced NUT Carcinoma × Etoposide × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡